The Changing Landscape of Glaucoma Therapies: Part 1 - Live
Overview
This webinar will focus on caring for patients with glaucoma and will highlight the ways in which sustained-release therapies can help extend the follow-up interval. In the age of a pandemic, the benefits of longer lasting treatments that increase patient compliance with fewer patients visits has never been more important. There will be a live panel discussion and opportunity for Q & A. Supported by an independent educational grant from Allergan. Learning Objectives
At the completion of this educational activity, you will be better able to: - Categorize all available treatment regimens for mild-to-moderate primary open-angle glaucoma (POAG)
- Identify the effect that traditional topical glaucoma medications have on the ocular surface
- Describe ways to overcome issues with patient compliance and adherence
- Evaluate novel drug devices for the treatment of POAG as part of individualized therapy
- Compare the efficacy of novel therapeutics with traditional prostaglandins
Accreditation
Provided by Evolve Medical Education 
Accreditation Statement
Evolve Medical Education LLC (Evolve) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
Evolve designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Participation Method
In order to obtain credit, proceed through the program, complete the post-test, evaluation and submit for credit.
Course Viewing Requirements
Supported Browsers:
Internet Explorer 11 for Windows
Edge (recent versions; Chromium-based) for Windows
Google Chrome (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Mozilla Firefox (recent versions) for Windows, Mac OS, iOS, Android, or Linux
Safari (recent versions) for Mac OSX, or iOS
Hardware Requirements:
4GB+ RAM
Recommended internet speed 5Mbps+
Faculty and Disclosures
DISCLOSURE POLICY
Faculty:
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflicts of interest relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all conflicts of interest prior to this educational activity.
Preeya K. Gupta, MD
Clinical Medical Director Associate Professor of Ophthalmology Cornea & Refractive Surgery Duke University Eye Center Durham, North Carolina
Jeffrey M. Liebmann, MD
Shirlee and Bernard Brown Professor of Ophthalmology Director, Glaucoma Service Vice-chair, Department of Ophthalmology Columbia University Medical Center New York, New York
Felipe Medeiros, MD, PhD
Professor of Ophthalmology and Vice Chair of Technology Duke University Durham, North Carolina
Nathan M. Radcliffe, MD
Assistant Professor of Ophthalmology New York Eye Surgery Center New York Eye and Ear Infirmary of Mount Sinai New York, New York
DISCLOSURE POLICY It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent conflict of interests relating to the topics of this educational activity. Evolve has full policies in place that will identify and resolve all conflicts of interest prior to this educational activity. The following faculty/staff members have the following financial relationships with commercial interests:Nathan M. Radcliffe, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant and Speaker’s Bureau: Aerie PhnTrarmaceuticals, Alcon, Alimera Sciences, Allergan, Bausch + Lomb, Carl Zeiss Meditec, CATS, Ellex, Endo Optiks, Equinox, Glaukos, Iridex, Ivantis, Lumenis, New World Medical, Novartis, Ocular Science, Omeros, Reichert Technologies, Shire, and Sight Sciences. Preeya K. Gupta, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Alcon, Allergan, Aurea, Carl Zeiss Meditec, Johnson & Johnson Vision, Kala, New World Medical, NovaBay Pharmaceuticals, Novartis, Ocular Science, ReGenTree, Shire, Sight Sciences, Sun Pharmaceuticals, and TearLab. Jeffrey Liebman, MD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Allergan, Novartis, and Thea. Grant/Research Support: Carl Zeiss Meditec, and Topcon. Stock/Shareholder: Qura, and Sustained Nano Systems. Felipe Medeiros, MD, PhD, and/or spouse has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant: Aerie, Allergan, Biogen, Galimmedix, Novartis, and Stealth Biotherapeutics. Grant/Research Support: Carl Zeiss Meditec, Google, Inc., and Heidelberg Engineering. Stock/Shareholder: Google, Inc. The Evolve staff and planners have no financial relationships with commercial interests. Nisha Mukherjee, MD, peer reviewer, have no financial relationships with commercial interests.Disclaimer
OFF-LABEL STATEMENT This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. DISCLAIMER The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Allergan. System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
- Apple Safari for Mac OS and iOS
- Mozilla Firefox for Windows, Mac OS, iOS, and Android
- Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Release Date:
Expiration Date:
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!